Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $66.29.

A number of equities research analysts have weighed in on the company. HC Wainwright raised their price objective on Janux Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a research note on Thursday, May 9th. Scotiabank initiated coverage on shares of Janux Therapeutics in a report on Thursday, May 30th. They set a “sector perform” rating and a $47.00 price objective for the company. Wedbush boosted their target price on shares of Janux Therapeutics from $53.00 to $74.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 8th. Finally, Bank of America increased their price target on shares of Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, March 13th.

Janux Therapeutics Trading Down 1.8 %

NASDAQ JANX opened at $43.38 on Tuesday. The company’s fifty day simple moving average is $48.56 and its 200-day simple moving average is $29.01. The stock has a market cap of $2.25 billion, a P/E ratio of -35.56 and a beta of 3.71. Janux Therapeutics has a 52 week low of $5.65 and a 52 week high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. The firm had revenue of $1.25 million for the quarter, compared to analyst estimates of $0.98 million. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. On average, research analysts expect that Janux Therapeutics will post -1.34 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jay Lichter sold 1,500,000 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total transaction of $82,125,000.00. Following the completion of the transaction, the director now owns 633,673 shares of the company’s stock, valued at $34,693,596.75. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Janux Therapeutics news, CFO Tighe Reardon sold 822,721 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total value of $45,043,974.75. Following the sale, the chief financial officer now owns 633,673 shares in the company, valued at $34,693,596.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay Lichter sold 1,500,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $82,125,000.00. Following the transaction, the director now owns 633,673 shares of the company’s stock, valued at $34,693,596.75. The disclosure for this sale can be found here. Insiders have sold 3,000,000 shares of company stock valued at $164,250,000 over the last three months. Company insiders own 35.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in JANX. Virtu Financial LLC bought a new stake in shares of Janux Therapeutics during the first quarter valued at about $609,000. Artal Group S.A. acquired a new position in Janux Therapeutics during the 1st quarter valued at about $1,882,000. Janus Henderson Group PLC raised its position in shares of Janux Therapeutics by 1.8% during the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock worth $73,961,000 after buying an additional 34,069 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Janux Therapeutics in the 1st quarter worth approximately $739,000. Finally, Altitude Crest Partners Inc. acquired a new stake in shares of Janux Therapeutics in the 1st quarter worth approximately $7,278,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.